# Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

> **NCT03144856** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 39 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03144856
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-22
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03144856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03144856, "Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03144856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*